+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Intraperitoneal chemotherapy for stage III ovarian cancer



Intraperitoneal chemotherapy for stage III ovarian cancer



Journal of Clinical Oncology 21(5): 957; Author Reply 957-8




(PDF emailed within 0-6 h: $19.90)

Accession: 049394755

Download citation: RISBibTeXText

PMID: 12610205

DOI: 10.1200/JCO.2003.99.206


Related references

Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bulletin du Cancer 97(4): E23-E32, 2010

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecologic Oncology 100(1): 27-32, 2005

Re: intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecologic Oncology 102(1): 129; Author Reply 130-129; Author Reply 130, 2006

Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center. Gynecologic Oncology 142(1): 13-18, 2016

David Oliver: Accountability-individual blame versus a "just culture". Bmj 361: K1802-K1802, 2018

Optimally debulked stage III ovarian cancer: intraperitoneal or intravenous chemotherapy?. International Journal of Gynecological Cancer 20(11 Suppl 2): S20-S23, 2011

Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. Gynecologic Oncology 124(1): 59-62, 2012

Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. Gynecologic Oncology 143(3): 496-503, 2016

Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?. Critical Reviews in Oncology/Hematology 62(2): 137-147, 2006

Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?. Expert Review of Anticancer Therapy 8(7): 1135-1147, 2008

Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference?. Surgical Oncology 25(3): 164-170, 2016

Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecologic Oncology 112(3): 444-449, 2009

Combination of intraperitoneal hyperthermic perfusion chemotherapy (IHPC) with intraperitoneal chemotherapy as a treatment modality for persistent ovarian cancer. European Journal of Gynaecological Oncology 28(2): 128-130, 2007

A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer. Gynecologic Oncology 134(3): 468-472, 2014

Intraperitoneal chemotherapy ipc as consolidation treatment for stage iii iv ovarian cancer a pilot study of efficacy and tolerance. Journal of Cancer Research & Clinical Oncology 116(SUPPL PART 1): 691, 1990